Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$17.46 USD

17.46
4,274,858

-0.21 (-1.19%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $17.41 -0.05 (-0.29%) 4:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 15% (39 out of 252)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment

J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

    Teva Stock Falls as Novartis Brings Another Copaxone Generic

    Teva's (TEVA) shares fall as Novartis launches the second generic version of the 40 mg formulation of Copaxone

      Generic Drugmakers to Dump as Teva's Woes Continue in 2018

      The generic industry is facing several challenges pulling down several companies including Teva (TEVA).

        Teva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 View

        Teva's (TEVA) fourth-quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate.

          Teva (TEVA) Q4 Earnings & Sales Beat, 2018 View Disappoints

          Teva's (TEVA) fourth quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate. Stock crashes in pre-market trading.

            What's in the Cards for Teva (TEVA) This Earnings Season?

            Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone will hurt sales in the Specialty segment.

              Teva Completes Sale of Women's Health Segment for $703M

              Teva Pharmaceutical (TEVA) sells woman health specialty products for cash consideration of $703 million.

                Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb

                Amgen's (AMGN) antibody Aimovig meets all primary and secondary endpoints in a phase IIIb study on patients with episodic migraine, who have failed multiple prior preventive treatments.

                  Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies

                  Teva's (TEVA) two phase III studies evaluating the subcutaneous formulation of its asthma injection, Cinqair (reslizumab) fail to meet primary endpoints.

                    Teva's Trisenox Gets FDA Approval as First-Line Treatment

                    Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

                      Parkinson's Disease Space Again Under Spotlight This Week

                      Parkinson's Disease emerges a lucrative area in want of curative therapies in the space. To this end, many players work toward launching new treatments in the market.

                        AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU

                        AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.

                          Momenta & Mylan to Initiate Trial on Biosimilar of Eylea

                          Momenta (MNTA), in collaboration with Mylan (MYL), plans to initiate a trial of M710, a proposed biosimilar of leading ophthalmology drug Eylea, in the first half of 2018.

                            New Strong Sell Stocks for December 20th

                            Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                              Teva's Migraine Candidate Gets Priority Review From FDA

                              Teva's (TEVA) biologics license application (BLA) seeking approval for fremanezumab as a preventive treatment for migraine gets priority review from FDA

                                Kevin Cook headshot

                                Bear of the Day: Mallinckrodt PLC (MNK)

                                Generic drug makers are one of the worst performing industries this year and there's little sign of a turnaround

                                  Teva's New CEO Re-Shuffles Senior Management, Stock Up 7%

                                  Teva (TEVA) announced several organizational changes in order to save costs and improve productivity.

                                    Teva (TEVA) Stock Rises 5% on Reports of Massive Job Cuts

                                    Per an Israeli news release, Teva (TEVA) is expected to lay off 4000 employees

                                      AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

                                      AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.

                                        Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up

                                        Orexigen (OREX) reported a narrower-than-expected loss on higher Contrave volumes.

                                          BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates

                                          BioDelivery (BDSI) reports narrower-than-expected loss in Q3. Revenues also surpass estimates and increase significantly year over year.

                                            VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

                                            VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.

                                              Mylan (MYL) Misses on Earnings and Sales Estimates in Q3

                                              Mylan (MYL) missed both earnings and sales estimates in the third quarter of 2017 as EpiPen sales continue to decline further.

                                                Teva (TEVA) Stock Plunges 20% on Q3 Earnings Miss & View Cut

                                                Teva's (TEVA) third-quarter earnings missed estimates while revenues were in line. The company lowered its earnings and revenue guidance for 2017, for the second time this year.

                                                  Momenta's (MNTA) Biosimilar Study Fails, Q3 Loss Narrows

                                                  Momenta Pharmaceuticals (MNTA) study to evaluate a biosimilar version of Orencia failed which overshadowed the third-quarter results.